Advanced Filters
noise

migraine Clinical Trials

A listing of migraine medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 169 clinical trials
N Natalia Hernández

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.

18 years of age All Phase N/A

Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical …

19 years of age All Phase N/A

Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use

To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.

18 years of age All Phase N/A

Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy

Migraine is a common neurological disorder typically characterized by attacks of throbbing or pulsating headache on one side of the head of moderate to severe pain intensity. The purpose of this study is to evaluate fetal, maternal, and infant outcomes through 12 months of age among women exposed to Ubrelvy …

18 years of age Female Phase N/A

Aimovig Pregnancy Exposure Registry

The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.

18 - 99 years of age Female Phase N/A
K Kristin Veley, PharmD, MPH

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.

18 years of age Female Phase N/A
P Piero Barbanti, Prof, MD

(Italian Migraine Registry, I-GRAINE-NEW)

Rationale Understanding the mechanisms and evolution of migraine is hampered by its nature as a chronic "evolutionary" condition. Patients often come to migraine centers after years of disabling disease, non-specific diagnoses and ineffective treatments. When patients are admitted to the center is therefore the time when their history in terms …

18 years of age All Phase N/A
J Jalisa Santiago, BS

Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will evaluate the effectiveness of atogepant in treating adult participants with migraine in a real-world setting. Atogepant is an approved drug for preventive treatment of migraine in …

18 years of age All Phase N/A

Migraine and Neuropathic Pain in Osteoarthritis

The goal of this observational study is to estimate the frequency of neuropathic pain and migraines in a group of patients with osteoarthritis of the knees, hips, hands, spine or other joints. In addition to their usual care for osteoarthritis, participants will complete questionnaires to define migraine and neuropathic pain.

18 years of age All Phase N/A
P Piero Barbanti, Prof, MD

i-NEED: NEw migrainE Drugs Database

Approved by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) starting in 2018, anti-CGRP monoclonal antibodies (anti-CGRP mAbs) represent the first true revolution in the preventive treatment of migraine due to their selectivity and specificity. To date, four anti-CGRP mAbs have been developed for the preventive …

18 years of age All Phase N/A

Simplify language using AI